Venture&Growth
Location
Munich, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Venture&Growth
Shoulder Innovations
Shoulder Innovations is a US-based medical device company that is commercializing a novel shoulder arthroplasty portfolio paired with an AI-enabled surgical planning software. The portfolio is anchored by Shoulder Innovations’ proprietary InSetTM glenoid fixing technology to solve the problem of
Venture&Growth
Acacia Pharma
Belgian Therapeutics company commercializing supportive care products to treat side effects of medical procedures.
Venture&Growth
ADCendo
Danish Therapeutics company focused on antibody-drug conjugates (ADCs) for the treatment of cancers.
